Over the weekend, Johnson & Johnson (NYSE:JNJ) shared data from its TARIS platform assets (TAR-210 and TAR-200) in patients with different types of bladder cancer. Goldman Sachs notes that the company has framed the platform as having a peak revenue potential of over $5 billion. The analyst states that Johnson & Johnson emphasized the ease of administering their TARIS platform device-based therapy from a clinical management perspective.  The process resembles placing a catheter in the bladder or cystoscopy, requiring no general anesthesia and ...